VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AVTR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
AVTRAvantor, Inc.
$10.03$6.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksAVTRFinancials

Avantor, Inc. (AVTR) Financials

10Y historyFree accessUpdated daily

Revenue growth has stalled at 0.0% in 2026Q1, while gross margins have compressed from 34.1% in 2024Q2 to 31.7% due to unfavorable product mix shifts.

AVTR Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Sales/Revenue6.55B6.55B6.78B6.97B7.51B7.39B6.39B6.04B5.86B1.25B691.3M
Revenue Growth %-1.99%-3.41%-2.64%-7.26%1.71%15.52%5.85%3%370.12%80.44%-
Cost of Goods Sold4.45B4.41B4.5B4.6B4.91B4.88B4.31B4.12B4.04B814.6M371.6M
COGS % of Revenue-67.35%66.4%66.07%65.35%66.12%67.46%68.2%68.97%65.3%53.75%
Gross Profit2.11B2.14B2.28B2.36B2.6B2.5B2.08B1.92B1.82B432.8M319.7M
Gross Margin %32.13%32.65%33.6%33.93%34.65%33.88%32.54%31.8%31.03%34.7%46.25%
Gross Profit Growth %--6.14%-3.57%-9.18%4%20.29%8.32%5.54%320.47%35.38%-
Operating Expenses2.38B2.39B1.19B1.67B1.47B1.53B1.37B1.37B1.41B643.2M309.8M
OpEx % of Revenue-36.41%17.61%23.93%19.6%20.72%21.49%22.66%23.98%51.56%44.81%
Selling, General & Admin1.21B1.6B1.64B1.51B1.47B1.53B1.37B1.37B1.41B643.2M309.8M
SG&A % of Revenue-24.35%24.19%21.62%19.6%20.72%21.49%22.66%23.98%51.56%44.81%
Research & Development000000000019.1M
R&D % of Revenue----------2.76%
Other Operating Expenses3M790.1M-446.6M160.8M0000000
Operating Income-278.6M-246.2M1.08B696.4M1.13B972.2M706.8M551.8M413.5M-210.4M9.9M
Operating Margin %-4.25%-3.76%15.99%10%15.04%13.16%11.05%9.14%7.05%-16.87%1.43%
Operating Income Growth %--122.7%55.77%-38.38%16.25%37.55%28.09%33.45%296.53%-2225.25%-
EBITDA136.9M164M1.49B1.1B1.54B1.35B1.1B950.7M818.1M-111.2M70.2M
EBITDA Margin %2.09%2.5%21.97%15.77%20.44%18.3%17.24%15.74%13.95%-8.91%10.15%
EBITDA Growth %-90.82%-89%35.64%-28.46%13.64%22.61%15.94%16.21%835.7%-258.4%-
D&A (Non-Cash Add-back)415.5M410.2M405.5M402.3M405.5M379.2M395.4M398.9M404.6M99.2M60.3M
EBIT-284.4M-271.5M1.07B695.3M1.12B970.4M369.9M480.6M410M-259.3M9.7M
Net Interest Income-172.4M-169.8M-218.8M-284.8M-265.8M-217.4M-307.6M-440M-523.8M-200.9M-80.3M
Interest Income10.5M0000000000
Interest Expense182.9M169.8M218.8M284.8M265.8M217.4M307.6M440M523.8M200.9M80.3M
Other Income/Expense-192.9M-195.1M-230.9M-285.9M-279.1M-219.2M-644.5M-511.2M-527.3M-249.8M-80.5M
Pretax Income-471.5M-441.3M853.9M410.5M851.1M753M62.3M40.6M-113.8M-460.2M-70.6M
Pretax Margin %-7.2%-6.74%12.59%5.89%11.33%10.19%0.97%0.67%-1.94%-36.89%-10.21%
Income Tax79.9M88.9M142.4M89.4M164.6M180.4M-54.3M2.8M-26.9M-314.9M10.1M
Effective Tax Rate %-16.95%-20.15%16.68%21.78%19.34%23.96%-87.16%6.9%23.64%68.43%-14.31%
Net Income-551.4M-530.2M711.5M321.1M686.5M572.6M116.6M37.8M-86.9M-112.7M-42.4M
Net Margin %-8.42%-8.09%10.49%4.61%9.14%7.75%1.82%0.63%-1.48%-9.03%-6.13%
Net Income Growth %-177.05%-174.52%121.58%-53.23%19.89%391.08%208.47%143.5%22.89%-165.8%-
Net Income (Continuing)-551.4M-530.2M711.5M321.1M686.5M572.6M116.6M37.8M-86.9M-145.3M-80.7M
Discontinued Operations00000000000
Minority Interest0000000000-135.7M
EPS (Diluted)-0.81-0.781.040.471.010.850.09-0.84-0.72-0.84-0.09
EPS Growth %-176.67%-175%121.28%-53.47%18.82%844.44%110.71%-16.67%14.29%-873.35%-
EPS (Basic)--0.781.050.481.020.860.09-0.84-0.72-0.84-0.09
Diluted Shares Outstanding679.3M679.3M681.9M678.4M679.4M599.6M583.4M401.2M496.5M496.5M491.3M
Basic Shares Outstanding678M678M680.3M675.6M650.9M590.5M576.3M401.2M496.5M496.5M491.3M
Dividend Payout Ratio-------82.8%---

Key Metrics

Growth RegimeContracting
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Persistent revenue contraction

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Persistent Revenue Contraction Trends

As indicated by the most recent quarterly data, Avantor's revenue growth has remained stagnant or negative, with the company reporting a 0.0% growth rate in 2026Q1 following a consistent pattern of year-over-year declines that suggest ongoing challenges in stabilizing its core bioprocessing and laboratory supply volumes.

The lack of top-line expansion appears to reflect a prolonged period of inventory destocking across the biopharma customer base. Investors should monitor whether this stagnation represents a structural shift in demand or merely a cyclical trough in the post-pandemic environment.

Structural Margin Compression Risks

Based on reported financial statements, Avantor's gross margins have drifted downward from 34.1% in 2024Q2 to 31.7% in 2026Q1, highlighting the difficulty of maintaining pricing power while navigating a mix shift toward lower-margin distributed products rather than proprietary high-purity chemical solutions.

The erosion of gross margin suggests that the company's distribution-heavy model is highly sensitive to competitive pricing pressures. This trend warrants further investigation into whether the company can successfully pivot its portfolio toward higher-value, single-use assemblies to restore historical profitability levels.

Operating Leverage Remains Under Pressure

According to the income statement history, operating margins have struggled to scale, fluctuating significantly and even turning negative in 2025Q3, which implies that the company's fixed cost base remains poorly aligned with current revenue levels during periods of volume volatility.

The inability to consistently expand operating income relative to gross profit suggests that SG&A expenses are not sufficiently flexible to offset revenue declines. This lack of operating leverage may indicate that the company is carrying excess overhead from its previous acquisition-led growth phase.

Earnings Volatility Masks Operational Reality

As reported in recent filings, the significant disparity between GAAP net income and operational performance, exemplified by the massive $711.8M net loss in 2025Q3, suggests that non-recurring charges and impairment events are heavily distorting the company's true earnings power for institutional investors.

The presence of large, non-cash charges indicates that previous capital allocation decisions may require downward valuation adjustments. Analysts should focus on adjusted metrics to determine if the underlying business remains cash-generative despite the headline volatility in reported net income.

Distribution Model Vulnerability Concerns

Based on the provided data, the company's reliance on a distribution-heavy revenue stream creates a structural risk, as evidenced by the 2025Q3 operating margin collapse, which suggests that the business lacks the defensive moat required to protect profitability during industry-wide demand downturns.

Short-sellers may focus on the potential for further margin compression if the company fails to increase its proprietary product mix. The current financial profile appears to lack the resilience of its more specialized peers, making it particularly susceptible to further inventory corrections.

AVTR — Frequently Asked Questions

Quick answers to the most common questions about buying AVTR stock.

What was Avantor, Inc.'s (AVTR) revenue in 2025?

For fiscal year 2025, Avantor, Inc. (AVTR) reported total revenue of $6.55B. This represents a 847.8% increase compared to $691.3M in 2016.

Is Avantor, Inc. (AVTR) profitable?

Avantor, Inc. (AVTR) reported a net loss of $530.2M for the fiscal year ending 2025.

What is Avantor, Inc.'s operating profit margin?

Avantor, Inc. (AVTR) reported an operating income of $-246.2M, resulting in an operating profit margin of -3.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Avantor, Inc.'s gross profit and gross margin?

Avantor, Inc. (AVTR) generated $2.14B in gross profit for the year, representing a gross profit margin of 32.7%. This demonstrates the company's core pricing power and production efficiency.